{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:39:41Z","timestamp":1792463981740,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008111","name":"Hainan Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["No. YSGZZ2024001"],"award-info":[{"award-number":["No. YSGZZ2024001"]}],"id":[{"id":"10.13039\/501100008111","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Specific Research Fund of the Innovation Platform for Academicians of Hainan Province","award":["No.YSPTZX202501"],"award-info":[{"award-number":["No.YSPTZX202501"]}]},{"name":"Cancer Innovative Research Program of Sun Yat-sen University Cancer Center","award":["CIRP-SYSUCC-0005"],"award-info":[{"award-number":["CIRP-SYSUCC-0005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-05085-3","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:58:09Z","timestamp":1784735889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining optimal treatment strategies for nasopharyngeal carcinoma based on the ninth edition TNM staging system: insights from a multicenter cohort study in an endemic region"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3212-0689","authenticated-orcid":false,"given":"Gaoyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqing","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjie","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1137-9349","authenticated-orcid":false,"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"10022","key":"5085_CR1","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","volume":"387","author":"MLK Chua","year":"2016","unstructured":"Chua MLK, Wee JTS, Hui EP, Cang ATC. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012\u201324.","journal-title":"Lancet"},{"issue":"11","key":"5085_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cac2.12218","volume":"41","author":"LL Tang","year":"2021","unstructured":"Tang LL, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond). 2021;41(11):1195\u2013227.","journal-title":"Cancer Commun (Lond)"},{"key":"5085_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/cncr.29795","volume":"122","author":"JJ Pan","year":"2016","unstructured":"Pan JJ, Ng WT, Zong JF, Chan LLK, O\u2019Sullivan B, Lin SJ, et al. Proposal for the 8th Edition of the AJCC\/UICC Staging System for Nasopharyngeal Cancer in the Era of Intensity-Modulated Radiotherapy. Cancer. 2016;122:546\u201358.","journal-title":"Cancer"},{"issue":"7","key":"5085_CR4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"YP Chen","year":"2021","unstructured":"Chen YP, Ismaila N, Chua MLK, Colevas AD, Robert H, Huang SH, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021;39(7):840\u201359.","journal-title":"J Clin Oncol"},{"issue":"8","key":"5085_CR5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jama.2022.13997","volume":"328","author":"LL Tang","year":"2022","unstructured":"Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, et al. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022;328(8):728\u201336.","journal-title":"JAMA"},{"issue":"23","key":"5085_CR6","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/jnci\/djr432","volume":"103","author":"QY Chen","year":"2011","unstructured":"Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, et al. Concurrent chemoradiotherapy vs. radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103(23):1761\u201370.","journal-title":"J Natl Cancer Inst"},{"key":"5085_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2018.10.020","volume":"110","author":"XY Li","year":"2019","unstructured":"Li XY, Chen QY, Sun XS, Liu SL, Yan JJ, Guo SS, et al. Ten-year outcomes of survival and toxicity for a phase III randomized trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer. 2019;110:24\u201331.","journal-title":"Eur J Cancer"},{"issue":"11","key":"5085_CR8","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509\u201320.","journal-title":"Lancet Oncol"},{"issue":"12","key":"5085_CR9","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019;381(12):1124\u201335.","journal-title":"N Engl J Med"},{"key":"5085_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398:303\u201313.","journal-title":"Lancet"},{"issue":"3","key":"5085_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2023.12.020","volume":"42","author":"XJ Du","year":"2024","unstructured":"Du XJ, Wang GY, Zhu XD, Han YQ, Lei F, Shen LF, et al. Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma. Cancer Cell. 2024;42(3):464\u201373.","journal-title":"Cancer Cell"},{"issue":"12","key":"5085_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jamaoncol.2024.4354","volume":"10","author":"JJ Pan","year":"2024","unstructured":"Pan JJ, Mai HQ, Ng WT, Hu CS, Li JG, Chen XZ, et al. Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification. JAMA Oncol. 2024;10(12):1627\u201335.","journal-title":"JAMA Oncol"},{"issue":"9","key":"5085_CR13","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/cncr.24201","volume":"115","author":"L Liu","year":"2009","unstructured":"Liu L, Liang S, Li L, Mao Y, Tang L, Tian L, et al. Prognostic impact of magnetic resonance imaging-detected cranial nerve involvement in nasopharyngeal carcinoma. Cancer. 2009;115(9):1995\u20132003.","journal-title":"Cancer"},{"issue":"6","key":"5085_CR14","doi-asserted-by":"publisher","first-page":"e100571","DOI":"10.1371\/journal.pone.0100571","volume":"9","author":"J Zong","year":"2014","unstructured":"Zong J, Lin S, Chen Y, Wang B, Xiao Y, Lin J, et al. Does MRI-detected cranial nerve involvement affect the prognosis of locally advanced nasopharyngeal carcinoma treated with intensity modulated radiotherapy? PLoS ONE. 2014;9(6):e100571.","journal-title":"PLoS ONE"},{"issue":"5","key":"5085_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.ijrobp.2018.12.009","volume":"103","author":"RL Bakst","year":"2019","unstructured":"Bakst RL, Glastonbury CM, Parvathaneni U, Katabi N, Hu KS, Yom SS. Perineural Invasion and Perineural Tumor Spread in Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2019;103(5):1109\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"5085_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00256-007-0409-0","volume":"37","author":"S Kamath","year":"2008","unstructured":"Kamath S, Venkatanarasimha N, Walsh MA, Hughes PM. MRI appearance of muscle denervation. Skeletal Radiol. 2008;37(5):397\u2013404.","journal-title":"Skeletal Radiol"},{"issue":"1","key":"5085_CR17","first-page":"22","volume":"22","author":"O Medvedev","year":"2022","unstructured":"Medvedev O, Hedesiu M, Ciurea A, Lenghel M, Rotar H, Dinu C, et al. Perineural spread in head and neck malignancies: imaging findings-an updated literature review. Bosn J Basic Med Sci. 2022;22(1):22\u201338.","journal-title":"Bosn J Basic Med Sci"},{"issue":"7","key":"5085_CR18","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/S1470-2045(24)00066-4","volume":"25","author":"C Henson","year":"2024","unstructured":"Henson C, Abou-Foul AK, Yu E, Glastonbury C, Huang SH, King AD, et al. Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024;25(7):e297\u2013307.","journal-title":"Lancet Oncol"},{"issue":"12","key":"5085_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.5732\/cjc.012.10095","volume":"31","author":"WF Li","year":"2012","unstructured":"Li WF, Sun Y, Chen M, Tang LL, Liu LZ, Mao YP, et al. Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation. Chin J Cancer. 2012;31(12):579\u201387.","journal-title":"Chin J Cancer"},{"issue":"5","key":"5085_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1278-3218(01)00117-2","volume":"5","author":"J Chavaudra","year":"2001","unstructured":"Chavaudra J, Bridier A. Definition of volumes in external radiotherapy: ICRU reports 50 and 62. Article in French. Cancer Radiother. 2001;5(5):472\u20138.","journal-title":"Cancer Radiother"},{"issue":"1","key":"5085_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/ije\/dyaa260","volume":"50","author":"MA Mansournia","year":"2021","unstructured":"Mansournia MA, Nazemipour M, Naimi AI, Gary SC, Campbell MJ. Reflection on modern methods: demystifying robust standard errors for epidemiologists. Int J Epidemiol. 2021;50(1):346\u201351.","journal-title":"Int J Epidemiol"},{"issue":"11","key":"5085_CR22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/sim.8502","volume":"39","author":"PC Austin","year":"2020","unstructured":"Austin PC, Cafri G. Variance estimation when using propensity-score matching with replacement with survival or time-to-event outcomes. Stat Med. 2020;39(11):1623\u201340.","journal-title":"Stat Med"},{"issue":"1","key":"5085_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/bimj.200810488","volume":"51","author":"PC Austin","year":"2009","unstructured":"Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J. 2009;51(1):171\u201384.","journal-title":"Biom J"},{"issue":"3","key":"5085_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1148\/radiol.14140035","volume":"271","author":"EF Halpern","year":"2014","unstructured":"Halpern EF. Behind the numbers: inverse probability weighting. Radiology. 2014;271(3):625\u20138.","journal-title":"Radiology"},{"issue":"28","key":"5085_CR25","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"issue":"1","key":"5085_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2217\/cer.13.89","volume":"3","author":"BJ Borah","year":"2014","unstructured":"Borah BJ, Moriarty JP, Crown WH, Doshi JA. Applications of propensity score methods in observational comparative effectiveness and safety research: where have we come and where should we go? J Comp Eff Res. 2014;3(1):63\u201378.","journal-title":"J Comp Eff Res"},{"issue":"10192","key":"5085_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J, et al. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64\u201380.","journal-title":"Lancet"},{"issue":"8","key":"5085_CR28","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J, Hu C, Xu M, Li W, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162\u201374.","journal-title":"Lancet Oncol"},{"issue":"9","key":"5085_CR29","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536\u201343.","journal-title":"Nat Med"},{"issue":"6","key":"5085_CR30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41(6):1061\u201372.","journal-title":"Cancer Cell"},{"issue":"11","key":"5085_CR31","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JCO.21.01467","volume":"40","author":"XY Li","year":"2022","unstructured":"Li XY, Luo DH, Guo L, Mo HY, Sun R, Guo SS, et al. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial. J Clin Oncol. 2022;40(11):1163\u201373.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5085_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4143\/crt.2014.141","volume":"47","author":"MK Kang","year":"2015","unstructured":"Kang MK, Oh D, Cho KH, Moon SH, Wu HG, Heo DS, et al. Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy. Cancer Res Treat. 2015;47(4):871\u20138.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"5085_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13014-020-01508-4","volume":"15","author":"O Aftab","year":"2020","unstructured":"Aftab O, Liao S, Zhang R, Tang N, Luo M, Zhang B, et al. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Radiat Oncol. 2020;15(1):66.","journal-title":"Radiat Oncol"},{"key":"5085_CR34","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3389\/fonc.2020.01314","volume":"10","author":"X Huang","year":"2020","unstructured":"Huang X, Chen X, Zhao C, Wang J, Wang K, Wang L, et al. Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy Does Not Improve Treatment Outcomes for Stage II Nasopharyngeal Carcinoma: A Phase 2 Multicenter Clinical Trial. Front Oncol. 2020;10:1314.","journal-title":"Front Oncol"},{"key":"5085_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.radonc.2021.01.015","volume":"157","author":"Y Mao","year":"2021","unstructured":"Mao Y, Wang S, Lydiatt W, Shah JP, Colevas AD, Lee AWM, et al. Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. Radiother Oncol. 2021;157:114\u201321.","journal-title":"Radiother Oncol"},{"key":"5085_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.radonc.2021.10.018","volume":"165","author":"O Chin","year":"2021","unstructured":"Chin O, Yu E, O\u2019Sullivan B, Su J, Anais T, Siu L, et al. Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. Radiother Oncol. 2021;165:94\u2013102.","journal-title":"Radiother Oncol"},{"issue":"19","key":"5085_CR37","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1002\/cam4.3392","volume":"9","author":"CL Huang","year":"2020","unstructured":"Huang CL, Chen Y, Guo R, Mao YP, Xu C, Tian L, et al. Prognostic value of MRI-determined cervical lymph node size in nasopharyngeal carcinoma. Cancer Med. 2020;9(19):7100\u20136.","journal-title":"Cancer Med"},{"issue":"2","key":"5085_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijrobp.2012.09.003","volume":"86","author":"WF Li","year":"2013","unstructured":"Li WF, Sun Y, Mao YP, Chen L, Chen YY, Chen M, et al. Proposed lymph node staging system using the International Consensus Guidelines for lymph node levels is predictive for nasopharyngeal carcinoma patients from endemic areas treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86(2):249\u201356.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5085_CR39","doi-asserted-by":"publisher","first-page":"17378","DOI":"10.1038\/srep17378","volume":"5","author":"F Zhang","year":"2015","unstructured":"Zhang F, Zhang Y, Li WF, Liu X, Guo R, Sun Y, et al. Efficacy of concurrent chemotherapy for intermediate risk NPC in the intensity-modulated radiotherapy era: a propensity-matched analysis. Sci Rep. 2015;5:17378.","journal-title":"Sci Rep"},{"issue":"2","key":"5085_CR40","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/cncr.20358","volume":"101","author":"EP Hui","year":"2004","unstructured":"Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer. 2004;101(2):300\u20136.","journal-title":"Cancer"},{"issue":"1","key":"5085_CR41","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1634\/theoncologist.2017-0577","volume":"24","author":"L Chen","year":"2019","unstructured":"Chen L, Zhang Y, Lai SZ, Li WF, Hu WH, Sun R, et al. 10-year results of therapeutic ratio by intensity-modulated radiotherapy versus two-dimensional radiotherapy in patients with nasopharyngeal carcinoma. Oncologist. 2019;24(1):e38\u201345.","journal-title":"Oncologist"},{"key":"5085_CR42","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3389\/fonc.2019.01343","volume":"9","author":"C Xu","year":"2019","unstructured":"Xu C, Zhang S, Li WF, Chen L, Mao YP, Guo Y, et al. Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data. Front Oncol. 2019;9:1343.","journal-title":"Front Oncol"},{"issue":"5","key":"5085_CR43","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/cam4.2131","volume":"8","author":"LL Tang","year":"2019","unstructured":"Tang LL, Liang SB, Huang CL, Zhang F, Xu C, Mao YP, et al. The development and external validation of simplified T category classification for nasopharyngeal carcinoma to improve the prognostic value in the intensity-modulated radiotherapy era. Cancer Med. 2019;8(5):2213\u201322.","journal-title":"Cancer Med"},{"key":"5085_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.radonc.2019.01.021","volume":"134","author":"HJ Li","year":"2019","unstructured":"Li HJ, Hu YY, Huang L, Zhou J, Li JJ, Xie CB, et al. Subclassification of skull-base invasion for nasopharyngeal carcinoma using cluster, network and survival analyses: a double-center retrospective investigation. Radiother Oncol. 2019;134:37\u201343.","journal-title":"Radiother Oncol"},{"issue":"11","key":"5085_CR45","doi-asserted-by":"publisher","first-page":"7767","DOI":"10.1007\/s00330-022-08864-7","volume":"32","author":"S Li","year":"2022","unstructured":"Li S, Luo C, Huang W, Zhu S, Ruan G, Liu L, et al. Value of skull base invasion subclassification in nasopharyngeal carcinoma: implication for prognostic stratification and use of induction chemotherapy. Eur Radiol. 2022;32(11):7767\u201377.","journal-title":"Eur Radiol"},{"issue":"4","key":"5085_CR46","doi-asserted-by":"publisher","first-page":"e2408182","DOI":"10.1002\/advs.202408182","volume":"12","author":"S Zhu","year":"2025","unstructured":"Zhu S, Li S, Cao D, Luo C, Liang Z, Liang S, et al. Prognostic Value of Skull Base Foramen Invasion Subclassification in T Category Modification and Induction Chemotherapy Management for Nasopharyngeal Carcinoma: Post-Hoc Analysis of a Dual-Center Retrospective Cohort Study. Adv Sci (Weinh). 2025;12(4):e2408182.","journal-title":"Adv Sci (Weinh)"},{"issue":"9","key":"5085_CR47","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","volume":"6","author":"R You","year":"2020","unstructured":"You R, Liu YP, Huang PY, Zou X, Sun R, He YX, et al. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(9):1345\u201352.","journal-title":"JAMA Oncol"},{"key":"5085_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2017.02.029","volume":"77","author":"X Zou","year":"2017","unstructured":"Zou X, You R, Liu H, He YX, Xie GF, Xie ZH, et al. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer. 2017;77:117\u201326.","journal-title":"Eur J Cancer"},{"key":"5085_CR49","doi-asserted-by":"publisher","first-page":"175883592211124","DOI":"10.1177\/17588359221112486","volume":"14","author":"MX Zhang","year":"2022","unstructured":"Zhang MX, Liu T, You R, et al. Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study. Ther Adv Med Oncol. 2022;14:17588359221112486.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"5085_CR50","doi-asserted-by":"publisher","first-page":"e247086","DOI":"10.6004\/jnccn.2024.7086","volume":"23","author":"D Wen","year":"2025","unstructured":"Wen D, Jin J, Lin J, Zou X, Liu YL, Ding X, et al. Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era. J Natl Compr Canc Netw. 2025;23(4):e247086.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"5085_CR51","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1148\/radiol.2016151344","volume":"280","author":"L Shen","year":"2016","unstructured":"Shen L, Li W, Wang S, Xie G, Zeng Q, Chen C, et al. Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma. Radiology. 2016;280(3):805\u201314.","journal-title":"Radiology"},{"key":"5085_CR52","doi-asserted-by":"publisher","first-page":"115305","DOI":"10.1016\/j.ejca.2025.115305","volume":"219","author":"H Xu","year":"2025","unstructured":"Xu H, Hu Y, Xie T, Lu L, Yan Z, Chen X, et al. Validation and development of a refined M1 category for nasopharyngeal carcinoma based on the version-nine of AJCC\/UICC TNM staging system in the immunotherapy era: A multicenter cohort study. Eur J Cancer. 2025;219:115305.","journal-title":"Eur J Cancer"},{"issue":"20","key":"5085_CR53","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA. 2023;330(20):1961\u201370.","journal-title":"JAMA"},{"issue":"1","key":"5085_CR54","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv J, Chen Y, Zhou G, et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun. 2019;10(1):3941.","journal-title":"Nat Commun"},{"issue":"8","key":"5085_CR55","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","volume":"42","author":"J Lv","year":"2024","unstructured":"Lv J, Xu LX, Li ZX, Lin L, Wu CF, Quan TQ, et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. Cancer Cell. 2024;42(8):1401\u201314.","journal-title":"Cancer Cell"},{"issue":"8110","key":"5085_CR56","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41586-026-10244-w","volume":"652","author":"J Lv","year":"2026","unstructured":"Lv J, Zheng DX, Liang JH, Zhang N, Ye ZL, Xu XD, et al. Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma. Nature. 2026;652(8110):731\u20139.","journal-title":"Nature"},{"issue":"1","key":"5085_CR57","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12916-022-02463-5","volume":"20","author":"J Lv","year":"2022","unstructured":"Lv J, Wu C, Li J, Chen F, He S, He Q, et al. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics. BMC Med. 2022;20(1):268.","journal-title":"BMC Med"},{"key":"5085_CR58","doi-asserted-by":"publisher","first-page":"110032","DOI":"10.1016\/j.radonc.2023.110032","volume":"190","author":"CL Huang","year":"2024","unstructured":"Huang CL, Wang GY, Lou JH, Chen L, Li QJ, Li KP, et al. Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up. Radiother Oncol. 2024;190:110032.","journal-title":"Radiother Oncol"},{"issue":"10445","key":"5085_CR59","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024;403(10445):2720\u201331.","journal-title":"Lancet"},{"issue":"18","key":"5085_CR60","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2025.1132","volume":"333","author":"YL Liang","year":"2025","unstructured":"Liang YL, Liu X, Shen LF, Hu GY, Zou GR, Zhang N, et al. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial. JAMA. 2025;333(18):1589\u201398.","journal-title":"JAMA"},{"issue":"11","key":"5085_CR61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/jama.2025.13205","volume":"334","author":"C Xu","year":"2025","unstructured":"Xu C, Liang XY, Huang XQ, Jin F, Yang KY, Hu GY, et al. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. JAMA. 2025;334(11):973\u201383.","journal-title":"JAMA"},{"key":"5085_CR62","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1017\/erm.2026.10041","volume":"28","author":"J Dai","year":"2026","unstructured":"Dai J, Ma L, Han X, Li X, Han L, Wang W. Synergizing Radiotherapy and Immune Checkpoint Inhibitors in Malignant Solid Tumours: Mechanistic Insights and Translational Frontiers. Expert Rev Mol Med. 2026;28:e17.","journal-title":"Expert Rev Mol Med"},{"issue":"1","key":"5085_CR63","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1038\/s41467-024-52153-4","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ye SY, He S, Chi DM, Wang XZ, Wen YF, et al. Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma. Nat Commun. 2024;15(1):7713.","journal-title":"Nat Commun"},{"issue":"7","key":"5085_CR64","doi-asserted-by":"publisher","first-page":"102200","DOI":"10.1016\/j.xcrm.2025.102200","volume":"6","author":"SX Liu","year":"2025","unstructured":"Liu SX, Wu TW, Luo DH, Zhang LL, Zhou L, Luo YL, et al. Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell Rep Med. 2025;6(7):102200.","journal-title":"Cell Rep Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05085-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05085-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05085-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:02:37Z","timestamp":1792461757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05085-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5085"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05085-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol of this study was approved by the Ethics Committee of all centers (B2025-882-01) and performed in accordance with the guidelines of the World Medical Association (Declaration of Helsinki). Given the retrospective nature of the study and the use of anonymized patient data, the requirement for informed consent was waived for all patients.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"574"}}